FAILED TRIAL: Ph 3 RELATIVITY-098 trial of Opdualag™ (nivolumab and relatlimab-rmbw) in adjuvant, stage III-IV melanoma did not meet its primary endpoint of RFS February 19, 2025
ASCO GU 2025: PADCEV + KEYTRUDA Show Long-Term Efficacy in 1L Treatment of Locally Advanced or Metastatic Urothelial Cancer February 19, 2025
Linvoseltamab BLA Accepted for FDA Review for the Treatment of R/R Multiple Myeloma; PDUFA: 10Jul2025 February 19, 2025
IDEAYA and Gilead Sciences to Evaluate Combination of Trodelvy and IDE397 in MTAP-Deletion NSCLC February 19, 2025
IMFINZI perioperative regimen improved EFS and OS across MIBC patients regardless of cPR status in post-hoc exploratory analysis of NIAGARA Ph 3 trial February 19, 2025
FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer February 19, 2025
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic February 19, 2025
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies February 19, 2025
Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with R/R MZL Announced February 19, 2025
Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in Ph 1/2 TUSCANY Trial February 19, 2025
Data from Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median DOR of ~4 Years in Patients Achieving CR with JELMYTO Published in The Journal of Urology February 19, 2025
ASCO GU 2025: Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX + Opdivo in Patients with Advanced Kidney Cancer Announced February 19, 2025
ASCO GU 2025: New Data reported for Casdatifan in Patients with Metastatic Kidney Cancer February 19, 2025
ASCO GU 2025: New data for darolutamide confirm safety and improved efficacy across subgroups of patients with mHSPC February 19, 2025
ASCO-GU 2025: CRB-701 (SYS6002) Demonstrates Encouraging Safety and Broader Efficacy in Ph 1 Study February 19, 2025
Fast Track Designation granted from the U.S. FDA for Amezalpat to Treat Patients with HCC February 19, 2025
Positive FDA Guidance Received for Acceleration of Registration-Enabling MIRACLE Trial for R/R AML February 19, 2025
